Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 41.75m |
Free float | 38.53m |
P/E (TTM) | -- |
Market cap | 919.98m USD |
EPS (TTM) | -1.96 USD |
--
More ▼
Announcements
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
- Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum
- Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
- Oculis updates share capital for its existing at-the-market offering program
- Oculis Publishes Notification of Major Changes in Voting Rights
- Oculis Publishes Notification of Major Changes in Voting Rights
- Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
- Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða
- Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
More ▼